ROCKVILLE, Md. and
SHANGHAI, China,
Nov. 6,
2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the
"Company"), a global biotechnology company focused on bringing
highly differentiated medicines to patients around the world
through the discovery, development, and commercialization of novel
immunotherapies and biologics, today announced its in-person
participation in two conferences in November 2023, the
Jefferies London Healthcare Conference and the Piper Sandler
35th Annual Healthcare Conference. Details of the
conferences and management presentation are as follows:
Jefferies London Healthcare Conference (In Person)
Presentation
Time
|
Tuesday, November
14th at 10:30 a.m. GMT (5:30 a.m. EST)
|
Presenters
|
Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO
|
Webcast link
|
https://wsw.com/webcast/jeff287/imab/1828028 The
webcast will also be available under "Event Calendar" on I-Mab's IR
website
at http://ir.i-mabbiopharma.com/
|
Meetings
|
One-on-one and small
group meetings: Nov 14 – 16, 2023
|
Management
Participants
|
Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO
Mr. Tyler Ehler, Senior Director, Investor
Relations
|
For more information, please contact your Jefferies
representative.
Piper Sandler 35th Annual Healthcare Conference
(In Person)
Presentation
Time
|
Thursday, November
30th at 8:30 a.m. EST
|
Presenters
|
Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO
|
Meetings
|
One-on-one and small
group meetings: Nov 28 – 30, 2023
|
Management
Participants
|
Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO
Mr. Tyler Ehler, Senior Director, Investor
Relations
|
For more information, please contact your Piper Sandler
representative.
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biotechnology
company focused on bringing highly differentiated medicines to
patients around the world through the discovery, development, and
commercialization of novel immunotherapies and
biologics. I-Mab's innovative pipeline is driven by
internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market
development strategies, and through global partnerships. For
more information, please
visit https://www.i-mabbiopharma.com and follow us
on LinkedIn, X, formerly known as Twitter,
and WeChat.
I-Mab Contacts
Investors
|
Media
|
Tyler Ehler
|
Gigi Feng
|
Senior Director,
Investor Relations
|
Chief Communications
Officer
|
IR@i-mabbiopharma.com
|
PR@i-mabbiopharma.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-participation-at-jefferies-and-piper-conferences-in-november-301978319.html
SOURCE I-Mab